Insider · CIK 0001647542
Peter Altman
ceopresidentofficerdirector
Files at BCDA (BioCardia, Inc.). First filing Nov 19, 2024, latest Sep 30, 2026.
In brief
Peter Altman files SEC Form 4 as CEO, president and director at BCDA (BioCardia, Inc.). Since Nov 19, 2024, Peter Altman has reported 43 open-market buys worth $255k and 0 open-market sells worth $0, the latest filed on Sep 30, 2026.
After Peter Altman's past buys, the stock trailed the S&P 500 by a median 41.5% over six months (n = 26), and 0% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $1,030 of BCDA on Sep 29, 2026, filed Sep 30, 2026, scored 33 (weak). In the last 12 months: 21 buys worth $66k and 0 sells worth $0.
Track record
Negative
Past buys trailed the index over six months, median.
Median 6-month excess
-41.5%
after past buys, n = 26
Hit rate
0%
past buys that beat the index over 6 months
Open-market trades
43 / 0
$255k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BCDA: BioCardia, Inc.
BCDAOct 9, 2026 · close 1.04
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | BCDAbuy BioCardia, Inc. | $1,030 1,000 shares | +0% | +34% from low-34% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $1,995 1,900 shares | +0% | +36% from low-33% from high | |
| 28Weak | BCDAbuy BioCardia, Inc. | $872 800 shares | +0% | +42% from low-52% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $5,022 5,400 shares | +1% | +22% from low-59% from high | |
| 28Weak | BCDAbuy BioCardia, Inc. | $1,748 1,900 shares | +1% | +21% from low-59% from high | |
| 43Moderate | BCDAbuy BioCardia, Inc. | $3,900 5,000 shares | +1% | 0% from low-66% from high | |
| 38Weak | BCDAbuy BioCardia, Inc. | $415 500 shares | +0% | +4% from low-65% from high | |
| 43Moderate | BCDAbuy BioCardia, Inc. | $3,754 4,300 shares | +1% | 0% from low-67% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $7,175 7,500 shares | +2% | +21% from low-60% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $5,208 5,400 shares | +2% | +21% from low-60% from high | |
| 41Moderate | BioCardia, Inc. | $2,043 2,300 shares | +1% | +19% from low-61% from high | |
| 56Moderate | BioCardia, Inc. | $4,250 5,000 shares | +2% | 0% from low-64% from high | |
| 43Moderate | BCDAbuy BioCardia, Inc. | $1,570 1,700 shares | +1% | +6% from low-61% from high | |
| 48Moderate | BCDAbuy BioCardia, Inc. | $5,244 5,700 shares | +2% | 0% from low-63% from high | |
| 48Moderate | BCDAbuy BioCardia, Inc. | $5,202 5,100 shares | +2% | 0% from low-59% from high | |
| 48Moderate | BCDAbuy BioCardia, Inc. | $5,550 5,000 shares | +2% | +1% from low-65% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $1,230 1,000 shares | +0% | +15% from low-60% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $1,110 900 shares | +0% | +11% from low-61% from high | |
| 48Moderate | BCDAbuy BioCardia, Inc. | $5,650 5,000 shares | +2% | 0% from low-65% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $1,194 900 shares | +0% | +17% from low-59% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $1,444 1,100 shares | +0% | +15% from low-59% from high | |
| 76Notable | BioCardia, Inc. | $60k 48,000 shares | +28% | 0% from low-63% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $1,281 700 shares | +0% | +14% from low-39% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $183 100 shares | +0% | +11% from low-41% from high | |
| 43Moderate | BCDAbuy BioCardia, Inc. | $700 400 shares | +0% | +4% from low-45% from high | |
| 48Moderate | BCDAbuy BioCardia, Inc. | $2,989 1,700 shares | +1% | 0% from low-47% from high | |
| 63Notable | BioCardia, Inc. | $50k 24,096 shares | +17% | +11% from low-38% from high | |
| 33Weak | BCDAbuy BioCardia, Inc. | $221 100 shares | +0% | +23% from low-31% from high | |
| 38Weak | BCDAbuy BioCardia, Inc. | $4,651 2,300 shares | +2% | +12% from low-38% from high | |
| 25Weak | BCDAbuy BioCardia, Inc. | $1,028 400 shares | +0% | +58% from low-12% from high | |
| 76Notable | BioCardia, Inc. | $50k 26,246 shares | +23% | +6% from low-40% from high | |
| 48Moderate | BioCardia, Inc. | $214 100 shares | +0% | +11% from low-34% from high | |
| 58Moderate | BioCardia, Inc. | $1,206 600 shares | +1% | +5% from low-38% from high | |
| 43Moderate | BCDAbuy BioCardia, Inc. | $980 500 shares | +0% | +8% from low-36% from high | |
| 43Moderate | BCDAbuy BioCardia, Inc. | $1,632 800 shares | +1% | +9% from low-36% from high | |
| 34Weak | BCDAbuy BioCardia, Inc. | $2,435 1,100 shares | +1% | +23% from low-27% from high | |
| 38Weak | BCDAbuy BioCardia, Inc. | $2,688 1,200 shares | +1% | +14% from low-33% from high | |
| 37Weak | BioCardia, Inc. | $1,055 500 shares | +0% | +39% from low-18% from high | |
| 29Weak | BCDAbuy BioCardia, Inc. | $1,488 600 shares | +1% | +29% from low-24% from high | |
| 29Weak | BCDAbuy BioCardia, Inc. | $1,769 739 shares | +1% | +29% from low-24% from high | |
| 25Weak | BCDAbuy BioCardia, Inc. | $2,060 1,000 shares | +1% | - | |
| 25Weak | BCDAbuy BioCardia, Inc. | $555 250 shares | +0% | - | |
| 25Weak | BCDAbuy BioCardia, Inc. | $2,525 1,350 shares | +1% | - |
Transactions
The newest 50 of 68 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,000 | $1.03 | $1,030 | 384,885 | 13 d ago |
| Sep 23, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,900 | $1.05 | $1,995 | 383,885 | 20 d ago |
| Sep 3, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +800 | $1.09 | $872 | 381,985 | 39 d ago |
| Aug 17, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,400 | $0.93 | $5,022 | 381,115 | Aug 18, 2026 |
| Aug 13, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,900 | $0.92 | $1,748 | 375,785 | Aug 13, 2026 |
| Jul 29, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,000 | $0.78 | $3,900 | 373,885 | Jul 29, 2026 |
| Jul 17, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +500 | $0.83 | $415 | 368,885 | Jul 20, 2026 |
| Jul 14, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +2,800 | $0.88 | $2,464 | 366,885 | Jul 15, 2026 |
| Jul 15, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,500 | $0.86 | $1,290 | 368,385 | Jul 15, 2026 |
| Jul 8, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,500 | $0.97 | $5,335 | 367,485 | Jul 10, 2026 |
| Jul 9, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,000 | $0.90 | $900 | 368,485 | Jul 10, 2026 |
| Jul 10, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,000 | $0.94 | $940 | 369,485 | Jul 10, 2026 |
| Jul 8, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,400 | $0.96 | $5,208 | 361,985 | Jul 8, 2026 |
| Jul 2, 2026 | BCDA BioCardia, Inc. | FTax withholding Common Stock | -54,606 | $1.24 | $68k | 356,585 | Jul 7, 2026 |
| Jul 6, 2026 | BCDA BioCardia, Inc. | AGrant or award Stock Option (right to buy)derivative | +57,688 | $0.00 | $0 | 147,903 | Jul 7, 2026 |
| Jun 29, 2026 | BCDA BioCardia, Inc. | AGrant or award Common Stock | +110,625 | $1.20 | $133k | 411,191 | Jul 1, 2026 |
| Jun 17, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,500 | $0.85 | $1,275 | 299,766 | Jun 22, 2026 |
| Jun 18, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +800 | $0.96 | $768 | 300,566 | Jun 22, 2026 |
| Jun 9, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,000 | $0.85 | $4,250 | 298,266 | Jun 9, 2026 |
| May 19, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +200 | $0.95 | $190 | 291,766 | May 21, 2026 |
| May 20, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,500 | $0.92 | $1,380 | 293,266 | May 21, 2026 |
| May 18, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,700 | $0.92 | $5,244 | 291,566 | May 18, 2026 |
| May 15, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,100 | $1.02 | $5,202 | 285,866 | May 15, 2026 |
| Apr 29, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,000 | $1.11 | $5,550 | 280,766 | Apr 29, 2026 |
| Apr 20, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +600 | $1.23 | $738 | 275,366 | Apr 22, 2026 |
| Apr 21, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +400 | $1.23 | $492 | 275,766 | Apr 22, 2026 |
| Mar 24, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +600 | $1.24 | $744 | 274,466 | Mar 26, 2026 |
| Mar 25, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +300 | $1.22 | $366 | 274,766 | Mar 26, 2026 |
| Feb 4, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +5,000 | $1.13 | $5,650 | 273,866 | Feb 4, 2026 |
| Jan 20, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +600 | $1.32 | $792 | 268,566 | Jan 21, 2026 |
| Jan 21, 2026 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +300 | $1.34 | $402 | 268,866 | Jan 21, 2026 |
| Dec 16, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +200 | $1.37 | $274 | 267,066 | Dec 17, 2025 |
| Dec 17, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +900 | $1.30 | $1,170 | 267,966 | Dec 17, 2025 |
| Dec 8, 2025 | BCDA BioCardia, Inc. | AGrant or award Common Stock | +106,588 | $1.37 | $146k | 323,350 | Dec 10, 2025 |
| Dec 8, 2025 | BCDA BioCardia, Inc. | FTax withholding Common Stock | +56,484 | $1.37 | $77k | 266,866 | Dec 10, 2025 |
| Dec 8, 2025 | BCDA BioCardia, Inc. | AGrant or award Stock Option (right to buy)derivative | +38,000 | $0.00 | $0 | 90,215 | Dec 10, 2025 |
| Sep 19, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +48,000 | $1.25 | $60k | 216,762 | Sep 23, 2025 |
| Sep 19, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Warrant (right to buy)derivative | +48,000 | - | - | 143,612 | Sep 23, 2025 |
| Aug 22, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +700 | $1.83 | $1,281 | 168,762 | Aug 25, 2025 |
| Aug 13, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +100 | $1.83 | $183 | 168,062 | Aug 13, 2025 |
| Aug 12, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +400 | $1.75 | $700 | 167,962 | Aug 12, 2025 |
| Aug 11, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,700 | $1.76 | $2,989 | 167,562 | Aug 11, 2025 |
| Jun 30, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +24,096 | $2.08 | $50k | 165,862 | Jul 2, 2025 |
| Jun 30, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Warrant (right to buy)derivative | +24,096 | - | - | 95,612 | Jul 2, 2025 |
| May 30, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +100 | $2.21 | $221 | 141,766 | May 30, 2025 |
| May 20, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +1,600 | $2.08 | $3,328 | 140,966 | May 22, 2025 |
| May 22, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +700 | $1.89 | $1,323 | 141,666 | May 22, 2025 |
| May 14, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +100 | $2.99 | $299 | 139,066 | May 16, 2025 |
| May 16, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +300 | $2.43 | $730 | 139,366 | May 16, 2025 |
| Apr 23, 2025 | BCDA BioCardia, Inc. | POpen-market purchase Common Stock | +26,246 | $1.91 | $50k | 138,966 | Apr 25, 2025 |
50 of 68 rows shown.
Questions about Peter Altman
Answered from the filings on this page, as of the latest one.
Is Peter Altman buying or selling?
In the last 12 months Peter Altman reported 21 open-market buys worth $66k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $1,030 of BCDA on Sep 29, 2026. Grants, option exercises and tax withholding are not counted.
How did Peter Altman's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 41.5% over six months across 26 past buys, with 0% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Peter Altman file Form 4?
Peter Altman has filed Form 4 at BCDA (BioCardia, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.